Speech-Language Pathologists in Goshen, OH Accepting Medicare
4 Speech-Language Pathologists found. Showing 1 - 4
 Mrs. Laura Jean Plagens, M.S. CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6755 Linton Rd, Goshen, OH 45122 Phone: 513-722-2225 |
Mrs. Laura Scheffer, MA CCCSLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6696 Goshen Rd, Goshen, OH 45122 Phone: 513-722-2224 |
Carrie Boyd, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6692 Goshen Rd, Goshen, OH 45122 Phone: 513-722-2226 Fax: 513-722-2246 |
Nancy Bredemeier Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6696 Goshen Rd, Goshen, OH 45122 Phone: 513-722-2223 |
News Archive
Dwindling time fuels happier outlook
Older adults' attention tilts toward positive feelings and associations, despite the time-limited future that comes with advancing age, concludes a Brandeis study in the journal Psychology and Aging.
Physician shortage limits even insured patients' access to care
CBS News reports that just having insurance coverage "doesn't guarantee access" to health care, because there is s shortage of primary care doctors to provide treatment. "Baystate Medical Center is the second busiest emergency room in Massachusetts. They treat over 100,000 patients a year, but here's the thing: according to Dr. Niels Rathlev, who runs the ER, a quarter of them don't need his services." Rathlev says it would be "more appropriate" for those people to see a primary care doctor. "'The majority of patients who are frequent utilizers of the emergency department actually have insurance,' Rathlev said. 'They have a primary care physician, but they choose to come to the ER because they don't have access.'"
Catapult BioAccel announces funding of Kemeta
Catapult BioAccel, formerly named CatapultBio, has announced the funding of an Arizona-based early stage firm, Kemeta LLC, a company developing a revolutionary product for application in consumer health and medical markets.
FDA approves Boston Scientific's S-ICD system to treat sudden cardiac arrest
The U.S. Food and Drug Administration has granted Boston Scientific Corporation regulatory approval for its S-ICD System, the world's first and only commercially available subcutaneous implantable defibrillator (S-ICD) for the treatment of patients at risk for sudden cardiac arrest (SCA).
› Verified 9 days ago